These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32211111)

  • 1. Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy.
    Tan L; Su X; Li X; Li H; Hu B
    Int J Clin Exp Pathol; 2020; 13(2):286-294. PubMed ID: 32211111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of circulating pro-angiogenic miRNAs with cardiotoxicity induced by epirubicin/cyclophosphamide followed by docetaxel in patients with breast cancer.
    Qin X; Chang F; Wang Z; Jiang W
    Cancer Biomark; 2018; 23(4):473-484. PubMed ID: 30452398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy.
    Li H; Hu B; Guo Z; Jiang X; Su X; Zhang X
    Yonsei Med J; 2019 Jan; 60(1):30-37. PubMed ID: 30554488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-130a Increases and Predicts Cardiotoxicity during Adjuvant Chemotherapy in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.
    Feng Q; Ren Y; Hou A; Guo J; Mao Z; Liu S; Wang B; Bai Z; Hou X
    J Breast Cancer; 2021 Apr; 24(2):153-163. PubMed ID: 33818020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
    JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients.
    Liu H; Hu X; Wang L; Du T; Feng J; Li M; Liu L; Liu X
    Front Surg; 2022; 9():862617. PubMed ID: 35647022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab.
    Andersson AE; Linderholm B; Giglio D
    Acta Oncol; 2021 Apr; 60(4):475-481. PubMed ID: 33191817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer.
    Peddi PF; Fasching PA; Liu D; Quinaux E; Robert NJ; Valero V; Crown J; Falkson C; Brufsky A; Cunningham JM; Weinshilboum RM; Pienkowski T; Eiermann W; Martín M; Bee V; Wang X; Wang L; Yang E; Slamon DJ; Hurvitz SA
    Clin Cancer Res; 2022 May; 28(9):1854-1862. PubMed ID: 35110416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients.
    Blancas I; Linares-Rodríguez M; Martín-Bravo C; Gómez-Peña C; Rodríguez-Serrano F
    Clin Transl Oncol; 2024 Oct; 26(10):2531-2540. PubMed ID: 38771533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen as adjuvant chemotherapy for breast cancer.
    Watanabe N; Otsuka S; Sasaki Y; Shimojima R; Wani Y; Uchino K
    Breast Care (Basel); 2014 Feb; 9(1):46-51. PubMed ID: 24803887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
    Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
    J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.
    Cochet A; Quilichini G; Dygai-Cochet I; Touzery C; Toubeau M; Berriolo-Riedinger A; Coudert B; Cottin Y; Fumoleau P; Brunotte F
    Breast Cancer Res Treat; 2011 Dec; 130(3):845-54. PubMed ID: 21918836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab.
    Bouwer NI; Liesting C; Kofflard MJM; Sprangers-van Campen SM; Brugts JJ; Kitzen JJEM; Fouraux MA; Levin MD; Boersma E
    Cardiooncology; 2019; 5():4. PubMed ID: 32154011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
    Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
    Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Let-7f and miRNA-126 correlate with reduced cardiotoxicity risk in triple-negative breast cancer patients who underwent neoadjuvant chemotherapy.
    Zhu Z; Li X; Dong H; Ke S; Zheng WH
    Int J Clin Exp Pathol; 2018; 11(10):4987-4995. PubMed ID: 31949575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
    Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
    J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
    Ueno T; Masuda N; Sato N; Ohtani S; Yamamura J; Matsunami N; Kashiwaba M; Takano T; Takahashi M; Kaneko K; Ohno S; Morita S; Toi M
    Jpn J Clin Oncol; 2020 Jan; 50(1):3-11. PubMed ID: 31821506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.